Monisha Singh

Dr. Monisha Singh

Hospital Medicine
2201 Chapel Ave West, 
Cherry Hill, NJ 
2201 Chapel Ave West, 
Cherry Hill, NJ 

Overview

Monisha Singh is a primary care provider, practicing in Hospital Medicine in Cherry Hill, New Jersey.

Her clinical expertise encompasses Metastatic Insulinoma, Hypercalcemia, Milk-Alkali Syndrome, and Teratoma of the Mediastinum.

She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 6 clinical trials.

Graduate Institution

Touro College Of Osteopathic Medicine

Residency

Jefferson Health NJ

Specialties

Hospital Medicine

Hospital Affiliations

Jefferson Stratford Hospital
Jefferson Washington Township Hospital
Jefferson Cherry Hill Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Jefferson Cherry Hill Hospital
2201 Chapel Ave West, Cherry Hill, NJ 08002
Other Locations
Jefferson Stratford Hospital
18 East Laurel Road, Stratford, NJ 08084
435 Hurffville-Cross Keys Road, Turnersville, NJ 08012

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Hydroxytyrosol
Study Phase: Phase 2/Phase 3
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

6 Total Publications

Programmed death-ligand 1-high squamous cell carcinoma arising in ovarian teratoma: multi-modal therapy in a rare and aggressive malignancy.
Programmed death-ligand 1-high squamous cell carcinoma arising in ovarian teratoma: multi-modal therapy in a rare and aggressive malignancy.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 04, 2026
Similar Doctors
Expertise in
4
conditions
Dr. Muhammad A. Naeem
Hospital Medicine
Expertise in
4
conditions
Dr. Muhammad A. Naeem
Hospital Medicine

Jefferson Cherry Hill Hospital

2201 Chapel Ave West, 
Cherry Hill, NJ 
 (13.7 miles away)
856-513-4124
Languages Spoken:
English
See accepted insurances

Muhammad Naeem is a primary care provider, practicing in Hospital Medicine in Cherry Hill, New Jersey. Dr. Naeem is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Collapsed Lung, Congenital Cataract, Perrault Syndrome, Pancreaticoduodenectomy, and Endoscopy. Dr. Naeem is board certified in Internal Medicine.

Expertise in
25
conditions
Dr. Nauman Ahmad
Hospital Medicine
Expertise in
25
conditions
Dr. Nauman Ahmad
Hospital Medicine

TeamHealth Hospitalists

1 Riverview Plaza, 2 North, 
Red Bank, NJ 
 (11.1 miles away)
732-673-0286
Languages Spoken:
English
See accepted insurances

Nauman Ahmad is a primary care provider, practicing in Hospital Medicine in Red Bank, New Jersey. Dr. Ahmad is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Chemosis, Pneumonia, Sepsis, Cataract Removal, and Hernia Surgery.

Expertise in
23
conditions
Dr. Alexander Poulathas
Hospital Medicine
Expertise in
23
conditions
Dr. Alexander Poulathas
Hospital Medicine

Deborah Heart And Lung Center

200 Trenton Rd, 
Browns Mills, NJ 
 (30.5 miles away)
609-735-2925
Languages Spoken:
English
See accepted insurances

Alexander Poulathas is a Hospital Medicine provider practicing medicine in Browns Mills, New Jersey. Dr. Poulathas is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Heart Attack, Coronary Heart Disease, Necrosis, Heart Valve Repair, and Transcatheter Aortic Valve Replacement (TAVR).

Frequently Asked Questions about Dr. Monisha Singh

How do I make an appointment with Dr. Monisha Singh?

You can book an appointment with Dr. Monisha Singh by calling their office at 856-513-4124. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Monisha Singh a top-rated expert for Metastatic Insulinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Monisha Singh is classified as an Experienced expert for Metastatic Insulinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Monisha Singh specialize in?

While Dr. Monisha Singh is a Hospital Medicine, they have specific expertise in Metastatic Insulinoma, Hypercalcemia, and Milk-Alkali Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hospital Medicine.

Does Dr. Monisha Singh participate in research or clinical trials?

Yes. Dr. Monisha Singh has published 6 articles and abstracts on conditions like Metastatic Insulinoma. You can view a list of Dr. Monisha Singh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Monisha Singh accept my insurance?

Dr. Monisha Singh accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 856-513-4124 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile